Amputations under PMB Regulations: The Latest CMScript

By Staff Writer

January 20, 2023

Council for Medical Schemes latest CMScript focusing on amputations under PMB regulations. Amputation, the removal or loss of a body part, can drastically alter a person’s life. It impacts an individual’s mobility, work capabilities, social interactions, and independence. This article explores the causes of amputations, preventative measures, and the journey towards recovery and rehabilitation.

Life After Amputation: Recovery and Rehabilitation

Amputations due to traumatic and crush injuries, severe burns, diabetes mellitus, peripheral artery diseases, severe infections, and cancers must be funded in line with the PMB Regulations. This would include diagnosis, treatment, and care of PMBs irrespective of the member’s option.

Prosthetic limbs replace the function of the lost body part and are recommended based on the type of amputation, the patient’s general health, and the tasks expected to be performed using the prosthesis. However, not all individuals are suitable for a prosthetic limb, particularly those with serious health conditions such as heart failure.

Preventing Amputations

Preventing amputations involves addressing the underlying issues that may necessitate such a procedure. Lifestyle modifications, including a balanced diet, regular exercise, quitting smoking, and maintaining stable blood sugar, blood pressure, and cholesterol levels, are essential. Regular examination of the legs and feet for sores or changes in skin colour or temperature is also crucial.

Reference url

Recent Posts

Navigating Challenges for Small Countries to Access Innovative Medicines

By João L. Carapinha

July 31, 2025

Access to innovative medicines is a pressing issue for patients in smaller European countries. These nations often face significant barriers in obtaining timely and equitable healthcare solutions. The article "Ensuring access to innovative medicines for patients in smaller countries" (linked belo...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...
ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in Low-Income Countries

By Staff Writer

ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool. The update now includes access to long-acting injectable cabotegravir (CAB LA) for HIV treatment. This allows generic manufacturers to supply the therapy in 133 low- and middle-income countries (LMICs)....